[2] Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequencesof pegylation. Drug delivery 2006;13:399-409.
[3] Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, vonRoenn JH, et al. Randomized phase III trial of liposomal daunorubicin versusdoxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.Journal of clinical oncology : official journal of the American Society ofClinical Oncology 1996;14:2353-64.
[4] Ricotta R, Cerea G, Schiavetto I, Maugeri MR, PedrazzoliP, Siena S. Pegfilgrastim: current and future perspectives in the treatment ofchemotherapy-induced neutropenia. Future oncology 2006;2:667-76.
[5] Klibanov AL, Maruyama K, Torchilin VP, Huang L.Amphipathic polyethyleneglycols effectively prolong the circulation time ofliposomes. FEBS letters 1990;268:235-7.
[6]Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al.Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.Proceedings of the National Academy of Sciences of the United States of America2008;105:9343-8.